BHST
BIOHARVEST SCIENCES INC.
$3.20
0.00%
$72.5M
No data for this timeframe.
Vol
Market Cap$72.5M
Cap SizeMicro Cap
Inst. Holders9 funds
Inst. Value$3.8M
Inst. Activity1 buys / 0 sells
SEC Reports8
Recent Activity
May 28, 2026
SEC
BioHarvest Sciences filed its annual meeting proxy circular on Form 6-K, setting the AGM for June 25, 2026. The filing i
6-K — Impact 3/10
May 14, 2026
SEC
BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8% YoY), in line with its $42-$48M annual guidance. Net loss wid
6-K — Impact 5/10
May 14, 2026
SEC
BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8.2% YoY) but net loss widened to $2.6M from $2.3M, with operati
6-K — Impact 6/10
Inst.
TD Waterhouse Canada Inc. — ADD
23,827 shares ($101.7K)
Inst.
MORGAN STANLEY — DOUBLED
3,250 shares ($16.9K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.75 (Feb 2026)
Current $3.20
Low $10.00
Median $13.00
High $15.00
4 analysts
$10.00
$15.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 19, 2026 | Roth Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▼ -23.7% | $-0.14 — $-0.09 | 51% YoY | 4 |
| Next Q | $-0.10 ▼ -53.8% | $-0.13 — $-0.08 | 29% YoY | 4 |
| Current FY | $-0.41 ▼ -28.3% | $-0.46 — $-0.35 | 32% YoY | 4 |
| Next FY | $-0.17 ▼ -112.9% | $-0.32 — $-0.08 | 60% YoY | 4 |
Latest Reports
NEUTRAL
6-K
3/10
BioHarvest Sciences filed its annual meeting proxy circular on Form 6-K, setting the AGM for June 25, 2026. The filing i
May 28, 2026
NEUTRAL
6-K
5/10
BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8% YoY), in line with its $42-$48M annual guidance. Net loss wid
May 14, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Alyeska Investment Group, L.P. | $3.3M | — |
| KING LUTHER CAPITAL MANAGEMENT | $173.6K | — |
| TD Waterhouse Canada Inc. | $101.7K | ADD |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $71.2K | — |
| CITADEL ADVISORS LLC | $64.0K | — |
9 institutional holders with $3.8M total value (870,027 shares) as of 2026-Q1. Top holders: Alyeska, KING, TD. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 757,064 | $3.3M | 87.1% | — |
| 2 | KING LUTHER CAPITAL MANAGEMENT CORP | 40,000 | $173.6K | 4.6% | — |
| 3 | TD Waterhouse Canada Inc. | 23,827 | $101.7K | 2.7% | ADD +97.9% |
| 4 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 16,394 | $71.2K | 1.9% | — |
| 5 | CITADEL ADVISORS LLC | 14,753 | $64.0K | 1.7% | — |
| 6 | Vident Advisory, LLC | 11,576 | $50.2K | 1.3% | — |
| 7 | MORGAN STANLEY | 3,250 | $14.1K | 0.4% | DOUBLED +29445.5% |
| 8 | ROYAL BANK OF CANADA | 3,009 | $13.0K | 0.3% | DOUBLED +38244.4% |
| 9 | NATIONAL BANK OF CANADA /FI/ | 154 | $657.00 | 0.0% | ADD +40.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TD Waterhouse Canada Inc. | ADD | 12,042 | 23,827 | +97.9% | $101.7K | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 11 | 3,250 | +29445.5% | $16.9K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 61 | 11 | -82.0% | $104.00 | 2025-Q3 |
| ROYAL BANK OF CANADA | DOUBLED | 9 | 3,451 | +38244.4% | $23.0K | 2025-Q2 |
| NATIONAL BANK OF CANADA /FI/ | ADD | 110 | 154 | +40.0% | $1.0K | 2025-Q1 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 6 neutral. Avg impact: 4.1/10.
NEUTRAL
6-K
3/10
BioHarvest Sciences filed its annual meeting proxy circular on Form 6-K, setting the AGM for June 25
May 28, 2026
NEUTRAL
6-K
5/10
BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8% YoY), in line with its $42-$48M annual gu
May 14, 2026
BEARISH
6-K
6/10
BioHarvest Sciences reported Q1 2026 revenue of $8.5M (+8.2% YoY) but net loss widened to $2.6M from
May 14, 2026
NEUTRAL
6-K
3/10
BioHarvest Sciences appointed Nedira Salzman-Frenkel as VP of Business Development for its CDMO divi
May 14, 2026
NEUTRAL
6-K
4/10
BioHarvest Sciences announced a $1.2 million Stage 2 CDMO contract for developing a rare fragrance c
May 12, 2026
NEUTRAL
6-K
2/10
BioHarvest Sciences announced a strategic leadership transition: Co-Founder and Executive Chairman Z
May 11, 2026
NEUTRAL
6-K
3/10
BioHarvest Sciences announced a strategic leadership transition: co-founder and executive chairman D
Apr 29, 2026
BULLISH
6-K
7/10
BioHarvest Sciences announced that its VINIA brand has become the #1 resveratrol polyphenol nutraceu
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$12.75 mean target (Feb 2026)
$10.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $3.20 |
| Target Low | $10.00 |
| Target Mean | $12.75 |
| Target Median | $13.00 |
| Target High | $15.00 |
| # Analysts | 4 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.14 | $-0.09 | 51.0% | -23.7% | 0↑ 3↓ | $0.0B | 11.0% | 4 |
| Next Q 2026-09-30 |
$-0.10 | $-0.13 | $-0.08 | 28.6% | -53.8% | 0↑ 3↓ | $0.0B | 25.8% | 4 |
| Current FY 2026-12-31 |
$-0.41 | $-0.46 | $-0.35 | 32.1% | -28.3% | 0↑ 3↓ | $0.0B | 24.3% | 4 |
| Next FY 2027-12-31 |
$-0.17 | $-0.32 | $-0.08 | 59.5% | -112.9% | — | $0.1B | 37.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.117 | |
| 7d ago | $-0.095 | -0.022 |
| 30d ago | $-0.095 | -0.022 |
| 60d ago | $-0.050 | -0.067 |
| 90d ago | $-0.050 | -0.067 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 19, 2026 | Roth Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2025 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2025 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Jan 1, 2025 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.